Glycoconjugate vaccines

Bibliography

• Watt JP, Wolfson LJ, O'Brien KL, Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009;374(9693):903-11
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374(9693):893-902
   PubMed Web of Science ®Google Scholar
• Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat Q 1997;50(3-4):170-7
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129(6):1307-26
   PubMed Web of Science ®Google Scholar
• Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147(6):1100
   PubMed Web of Science ®Google Scholar
• Shurin PA, Rehmus JM, Johnson CE, Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993;123(5):801-10
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJ. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun 1991;59(5):1839-45
   PubMed Web of Science ®Google Scholar
• Dintzis RZ, Middleton MH, Dintzis HM. Studies on the immunogenicity and tolerogenicity of T-independent antigens. J Immunol 1983;131(5):2196-203
   PubMed Web of Science ®Google Scholar
• Velez CD, Lewis CJ, Kasper DL, Cobb BA. Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 2009;127(1):73-82
   PubMed Web of Science ®Google Scholar
• Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986;63(1):127-34
   PubMed Web of Science ®Google Scholar
• Al-Mazrou Y, Khalil M, Borrow R, Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun 2005;73(5):2932-9
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R, Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181(2):761-4
   PubMed Web of Science ®Google Scholar
• Koskela M, Leinonen M, Haiva VM, First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5(1):45-50
   PubMedGoogle Scholar
• Brynjolfsson SF, Henneken M, Bjarnarson SP, Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis 2012;205(3):422-30
   PubMed Web of Science ®Google Scholar
• Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 1989;143(10):3200-6
   PubMed Web of Science ®Google Scholar
• Zegers BJ, van der Giessen M, Reerink-Brongers EE, Stoop JW. The serum IgG subclass levels in healthy infants of 13 – 62 weeks of age. Clin Chim Acta 1980;101(2-3):265-9
   PubMed Web of Science ®Google Scholar
• Simell B, Lahdenkari M, Reunanen A, Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol 2008;15(9):1391-7
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9(3):185-94
   PubMed Web of Science ®Google Scholar
• Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1971;1(1):18-27
   PubMedGoogle Scholar
• Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999;17(Suppl 2):S28-36
   PubMedGoogle Scholar
• Costantino P, Rappuoli R, Berti F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin Drug Discov 2011;6(10):1045-66
   PubMed Web of Science ®Google Scholar
• Toellner KM, Gulbranson-Judge A, Taylor DR, Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med 1996;183(5):2303-12
   PubMed Web of Science ®Google Scholar
• Liu YJ, Zhang J, Lane PJ, Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol 1991;21(12):2951-62
   PubMed Web of Science ®Google Scholar
• Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 1998;161(3):1313-19
   PubMed Web of Science ®Google Scholar
• Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature 1991;354(6352):389-92
   PubMed Web of Science ®Google Scholar
• Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000;407(6804):636-42
   PubMed Web of Science ®Google Scholar
• Mamani-Matsuda M, Cosma A, Weller S, The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008;111(9):4653-9
   PubMed Web of Science ®Google Scholar
• Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol 2003;170(2):686-94
   PubMed Web of Science ®Google Scholar
• Horikawa K, Martin SW, Pogue SL, Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med 2007;204(4):759-69
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002;186(9):1353-7
   PubMed Web of Science ®Google Scholar
• Blanchard Rohner G, Snape MD, Kelly DF, The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008;180(4):2165-73
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9):1318-25
   PubMed Web of Science ®Google Scholar
• Richmond P, Goldblatt D, Fusco PC, Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999;18(7-8):641-6
   PubMed Web of Science ®Google Scholar
• Jackson LA, Jacobson RM, Reisinger KS, A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009;28(2):86-91
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines –- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60(3):72-6
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report. Available from: www.cdc.gov/abcs/index.html [Accessed 21 April 2012]
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report 2011 - Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Available from: ecdc.europa.eu. [ Accessed 21 April, 2012].
   Google Scholar
• Dyas A, George RH. Ten years' experience of Haemophilus influenzae infection at Birmingham Children's Hospital. J Infect 1986;13(2):179-85
   PubMed Web of Science ®Google Scholar
• Stephenson WP, Doern G, Gantz N, Pharyngeal carriage rates of Haemophilus influenzae, type b and non-b, and prevalence of ampicillin-resistant Haemophilus influenzae among healthy day-care children in central Massachusetts. Am J Epidemiol 1985;122(5):868-75
   PubMed Web of Science ®Google Scholar
• Makela PH, Peltola H, Kayhty H, Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977;136(Suppl):S43-50
   PubMed Web of Science ®Google Scholar
• Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310(24):1561-6
   PubMed Web of Science ®Google Scholar
• Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984;74(5):857-65
   PubMed Web of Science ®Google Scholar
• Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977;60(5):730-7
   PubMed Web of Science ®Google Scholar
• Kayhty H, Eskola J, Peltola H, Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991;145(2):223-7
   PubMedGoogle Scholar
• Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;120(2 Pt 1):184-9
   PubMed Web of Science ®Google Scholar
• Berkowitz CD, Ward JI, Meier K, Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr 1987;110(4):509-14
   PubMed Web of Science ®Google Scholar
• Ahonkhai VI, Lukacs LJ, Jonas LC, Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation. Pediatrics 1990;85(4 Pt 2):676-81
   PubMed Web of Science ®Google Scholar
• Granoff DM, Anderson EL, Osterholm MT, Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992;121(2):187-94
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999;354(9195):2063-8
   PubMed Web of Science ®Google Scholar
• Sturgess AW, Rush K, Charbonneau RJ, Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 1999;17(9-10):1169-78
   PubMed Web of Science ®Google Scholar
• Botet Asensi FI, Veronese A, Del Carmen Otero M, Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatr 2003;92(5):541-5
   PubMed Web of Science ®Google Scholar
• McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361(9368):1521-3
   PubMed Web of Science ®Google Scholar
• Trotter CL, McVernon J, Andrews NJ, Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003;361(9368):1523-4
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heys M, Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008;93(8):665-9
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Bradley R, Palmer P. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. J Pediatr 1993;122(3):410-13
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010;17(1):154-9
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics Act-Hib; Sanofi Pasteur, USA. Available from: www.immunize.org [Accessed 27 June] [2012]
   Google Scholar
• Summary of product characteristics Liquid PedVax-Hib; Merck & Co., Inc., USA. Available from: www.immunize.org [Accessed 27 June 2012]
   Google Scholar
• Summary of product characteristics Hiberix; GlaxoSmithKline, Belgium. Available from: www.immunize.org [Accessed 27 June] [2012]
   Google Scholar
• Bar-On ES, Goldberg E, Fraser A, Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2009(3):CD005530
   Google Scholar
• Eskola J, Kayhty H, Takala AK, A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against Invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323(20):1381-7
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J 1992;11(8):610-13
   PubMed Web of Science ®Google Scholar
• Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990;323(20):1393-401
   PubMed Web of Science ®Google Scholar
• Bulkow LR, Wainwright RB, Letson GW, Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993;12(6):484-92
   PubMed Web of Science ®Google Scholar
• Santosham M, Wolff M, Reid R, The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324(25):1767-72
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children–United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998;47(46):993-8
   PubMedGoogle Scholar
• Dagan R, Fraser D, Greif Z, A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Pediatr Infect Dis J 1998;17(9 Suppl):S198-203
   PubMed Web of Science ®Google Scholar
• Hargreaves RM, Slack MP, Howard AJ, Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ 1996;312(7024):160-1
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V, Deutschland Study Group. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004;23(10):944-50
   PubMed Web of Science ®Google Scholar
• Forleo-Neto E, de Oliveira CF, Maluf EM, Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis 1999;180(4):1153-8
   PubMed Web of Science ®Google Scholar
• Trotter CL, Chandra M, Cano R, A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007;31(1):27-36
   PubMed Web of Science ®Google Scholar
• Broker M, Jacobsson S, Detora L, Increase of meningococcal serogroup Y cases in Europe: A reason for concern? Hum Vaccin Immunother 2012;8(5):685-8
   PubMed Web of Science ®Google Scholar
• Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15:967-79
   PubMed Web of Science ®Google Scholar
• Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93(4):341-53
   PubMed Web of Science ®Google Scholar
• World Health Organization (2005) Geneva. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. WER 2005;80(37):313-20
   Google Scholar
• Handysides S, Spanjaard L, Levy-Bruhl D, Meningococcal infection in pilgrims returning from the Haj: update from Europe and beyond. Euro Surveill. 2000;4(17):pii = 1614. Available from: www.euro surveillance.org/ViewArticle.aspx?ArticleId = 1614 [Accessed 29 June 2012]
   Google Scholar
• World Health Organization. Global Alert and Response (GAR). Meningococcal disease: situation in the African meningitis belt. 24th May, 2012. Available from: http://www.who.int/csr/don/2012_05_24/en/index.html [Accessed 28 May 2012]
   Google Scholar
• Delrieu I, Yaro S, Tamekloe TA, Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011;6(5):e19513
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69(3):1568-73
   PubMed Web of Science ®Google Scholar
• Peltola H, Makela H, Kayhty H, Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297(13):686-91
   PubMed Web of Science ®Google Scholar
• Granoff DM, Maslanka SE, Carlone GM, A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5(4):479-85
   PubMedGoogle Scholar
• World Health Organization. Requirements for meningococcal polysaccharide vaccine (Requirements for Biological Substances No.23). In: WHO expert committee on biological standardization. Twenty-seventh report; Geneva: 1976; Annex 2 (WHO Technical Report Series, No 594)
   Google Scholar
• Shao PL, Chang LY, Hsieh SM, Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease. J Formos Med Assoc 2009;108(7):539-47
   PubMed Web of Science ®Google Scholar
• Lepow ML, Beeler J, Randolph M, Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154(6):1033-6
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979;140(5):690-7
   PubMed Web of Science ®Google Scholar
• Kayhty H, Karanko V, Peltola H, Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 1980;142(6):861-8
   PubMed Web of Science ®Google Scholar
• Zangwill KM, Stout RW, Carlone GM, Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994;169(4):847-52
   PubMed Web of Science ®Google Scholar
• Reingold AL, Broome CV, Hightower AW, Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. The Lancet 1985;2(8447):114-18
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obara S, Deeks J, Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. Vaccine 1999;17(23-24):3086-93
   PubMed Web of Science ®Google Scholar
• Findlow H, Sow S, Borrow R, Meningococcal group C and w135 immunological hyporesponsiveness in African toddlers. Clin Vaccine Immunol 2011;18(9):1492-6
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159(10):907-13
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001;184(3):377-80
   PubMed Web of Science ®Google Scholar
• English M, MacLennan JM, Bowen-Morris JM, A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000;19(9-10):1232-8
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183(1):160-3
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998;280(19):1685-9
   PubMed Web of Science ®Google Scholar
• Choo S, Zuckerman J, Goilav C, Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000;18(24):2686-92
   PubMed Web of Science ®Google Scholar
• Richmond P, Goldblatt D, Fusco PC, Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999;18(7-8):641-6
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N, Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009;16(2):194-9
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R, Andrews N, Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatr Infect Dis J 2012;31(6):616-22
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365-7
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Green B, Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005;24(2):128-31
   PubMed Web of Science ®Google Scholar
• Ishola DA Jr, Borrow R, Findlow H, Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction. Clin Vaccine Immunol 2012;19(8):1126-30
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009;35(ACS-3):1-40
   Google Scholar
• Snape MD, Kelly DF, Lewis S, Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336(7659):1487-91
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics; Meningitec, Wyeth Pharmaceuticals. Available from: www.medicines.org.uk/emc [Accessed 30 June 2012]
   Google Scholar
• Summary of product characteristics; Menjugate, Sanofi Pasteur, MSD. Available from: www.medicines.org.uk/emc [Accessed 30 June 2012]
   Google Scholar
• Summary of product characteristics: NeisVac-C, Baxter Vaccines
   Google Scholar
• Medicines and Healthcare products regulatory agency (MHRA). Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccine. 2002. Available from: http://www.mhra. gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2015729 [Accessed 30 June, 2012]
   Google Scholar
• Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum Vaccin 2007;3(2):59-63
   PubMed Web of Science ®Google Scholar
• Taylor B, Andrews N, Stowe J, No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Arch Dis Child 2007;92(10):887-9
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boucher RM, Ouakki M. Risk of Guillain-Barre syndrome following serogroup C meningococcal conjugate vaccine in Quebec. Canada. Clin Infect Dis 2008;46(8):e75-7
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009;27(Suppl 2):B20-9
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197(5):737-43
   PubMed Web of Science ®Google Scholar
• Djingarey MH, Barry R, Bonkoungou M, Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012;30(Suppl 2):B40-5
   PubMedGoogle Scholar
• Meningitis Vaccine Project. MenAfriVacTM reaches three new African countries. Available from: http://www.meningvax.org/ [Accessed 19 August 2012]
   Google Scholar
• Kshirsagar N, Mur N, Thatte U, Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007;25(Suppl 1):A101-7
   PubMedGoogle Scholar
• Sow SO, Okoko BJ, Diallo A, Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364(24):2293-304
   PubMed Web of Science ®Google Scholar
• Program for Appropriate Technology in Health (PATH). Dramatic fall in cases of meningitis A in three West African nations after new vaccine introduction. Press Release. 2011. Available from: http://www.path.org/news/pr110609-menafrivac-results.php [Accessed 25 June 2012]
   Google Scholar
• Anderson EL, Bowers T, Mink CM, Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62(8):3391-5
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Garba A, Ethevenaux C, Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 2004;22(25-26):3303-11
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chiu SS, Wong VK, Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 1996;275(19):1499-503
   PubMed Web of Science ®Google Scholar
• Borrow R, Fox AJ, Richmond PC, Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiol Infect 2000;124(3):427-32
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J, Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001;183(1):97-104
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Product information-package insert: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine Menactra. Sanofi Pasteur, Inc., US Department of Health and Human Services, Food and Drug Administration. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf [Accessed 30 June 2012]
   Google Scholar
• Pichichero M, Casey J, Blatter M, Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24(1):57-62
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011;30(4):e56-62
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009;27(1):161-8
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011;30(3):e41-8
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009;49(1):e1-10
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Baxter R, Block SL, Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009;16(12):1810-15
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011;29(25):4264-73
   PubMed Web of Science ®Google Scholar
• Rennels M, King J Jr, Ryall R, Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23(5):429-35
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299(2):173-84
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006;193(6):821-8
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics; Menveo, Novartis Vaccines. Available from: www.medicines.org.uk/emc [Accessed 30 June 2012]
   Google Scholar
• Quiambao B, Jain H, Bavdekar A, Persistence of immune response to a candidate meningococcal tetravalent tetanus toxoid-conjugate vaccine (MenACWY-TT) in healty Asian adolescents, 2-years after vaccination. 30th Annual Meeting of the European Society for Paediatric Infectious Diseases; 8 – 12th May; Thessaloniki, Greece
   Google Scholar
• Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005;24(2):132-6
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Antibody persistence up to 36 months following vaccination with MenACWY-TT in children aged 2-10 years. 30th Annual Meeting of the European Society for Paediatric Infectious Diseases; 8 – 12th May; Thessaloniki, Greece
   Google Scholar
• Vesikari T, Forsten A, Bianco V, Persistence of immune response to a candidate tetravelant tetanus toxoid-conjugate vaccine (MenACWY-TT) in toddlers, 2 years after vaccination. 30th Annual Meeting of the European Society for Paediatric Infectious Diseases; 8 – 12th May; Thessaloniki, Greece
   Google Scholar
• Miller JM, Mesaros N, Van Der Wielen M, Baine Y. Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv Prev Med 2011;2011:846756
   Google Scholar
• Calix JJ, Nahm MH. A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis 2010;202(1):29-38
   PubMed Web of Science ®Google Scholar
• Kilpi T, Herva E, Kaijalainen T, Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001;20(7):654-62
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7(10): pii e1000348
   PubMed Web of Science ®Google Scholar
• Torzillo PJ, Hanna JN, Morey F, Invasive pneumococcal disease in central Australia. Med J Aust 1995;162(4):182-6
   PubMed Web of Science ®Google Scholar
• Cortese MM, Wolff M, Almeido-Hill J, High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med 1992;152(11):2277-82
   PubMed Web of Science ®Google Scholar
• Bennett NM, Buffington J, LaForce FM. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 1992;82(11):1513-16
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Hill PC, Cheung YB, Akisanya A, Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 2008;46(6):807-14
   PubMed Web of Science ®Google Scholar
• World Health Organization. Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. World Health Organization; Geneva, Switzerland: 2009
   Google Scholar
• Black S, Shinefield H, Fireman B, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19(3):187-95
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-8
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Moulton LH, Reid R, Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003;362(9381):355-61
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006;13(3):356-60
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ, Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148(6):1136-59
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Update: pneumococcal polysaccharide vaccine usage–United States. MMWR Morb Mortal Wkly Rep 1984;33(20):273-6, 281.
   PubMedGoogle Scholar
• Shapiro ED, Berg AT, Austrian R, The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325(21):1453-60
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008(1):CD000422
   PubMed Web of Science ®Google Scholar
• Riley ID, Lehmann D, Alpers MP, Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986;2(8512):877-81
   PubMed Web of Science ®Google Scholar
• Fiore AE, Levine OS, Elliott JA, Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 1999;Nov-Dec5(6):828-31
   PubMed Web of Science ®Google Scholar
• Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984;149(6):861-9
   PubMed Web of Science ®Google Scholar
• Ortqvist A, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007;25(13):2445-50
   PubMed Web of Science ®Google Scholar
• Musher DM, Luchi MJ, Watson DA, Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990;161(4):728-35
   PubMed Web of Science ®Google Scholar
• Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003;22(1):96-103
   PubMed Web of Science ®Google Scholar
• Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148(1):131-7
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L, Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006;25(4):312-19
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL, Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998;101(4 Pt 1):604-11
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-76
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126(3):e493-505
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28(25):4192-203
   PubMed Web of Science ®Google Scholar
• Snape MD, Klinger CL, Daniels ED, Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010;29(12):e80-90
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Hogh B, Bergsaker MR, Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009;28(10):e276-82
   PubMedGoogle Scholar
• Gimenez-Sanchez F, Kieninger DM, Kueper K, 501 and 006 study groups. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(35):6042-8
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, 3007 Study Group. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J 2012;31(4):392-9
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Francois N, Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 2011;30(9):e170-8
   PubMed Web of Science ®Google Scholar
• Grimprel E, Laudat F, Patterson S, Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 2011;29(52):9675-83
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 2011;30(8):e130-41
   PubMed Web of Science ®Google Scholar
• Sobanjo A, Vesikari T, Malacaman E, Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in toddlers previously immunized with 7-valent pneumococcal conjugate vaccine (PCV7). Poster abstract. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 7 – 11 June 2011; The Hague, The Netherlands
   Google Scholar
• Wysockii J, Daniels ED, Sarkozy DA, Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to previous vaccination. 27th Annual meeting of the European Society for Paediatric Infectious Diseases; 9 – 13 June 2009; Brussels, Belgium
   Google Scholar
• Madhi SA, Kuwanda L, Cutland C, Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24(5):410-16
   PubMed Web of Science ®Google Scholar
• Lin PL, Michaels MG, Green M, Safety and immunogenicity of the American Academy of Pediatrics–recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005;116(1):160-7
   PubMed Web of Science ®Google Scholar
• Johnson MA, Burbidge P, Haston M, Persistence and functional activity of responses to 7-valent pneumococcal conjugate compared to 23 valent pneumococcal polysaccharide vaccine in the elderly. Poster No 195 presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 11 – 15th March 2012; Iguacu Falls, Brazil
   Google Scholar
• Summary of product characterisitics; Prevenar 13; Pfizer. Available from: www.medicines. org.uk/emc [Accessed 27 May 2012]
   Google Scholar
• Musey L. Safety, tolerability, and immunogenicity of 15-Valent pneumococcal conjugate vaccine (PCV15) in healthy adults. Poster abstract 658. 49th Annual Meeting of the Infectious Disease Society of America (IDSA); 20 – 23 October 2011; Boston, USA
   Google Scholar
• Hicks LA, Harrison LH, Flannery B, Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196(9):1346-54
   PubMed Web of Science ®Google Scholar
• Cooper D, Yu X, Sidhu M, The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29(41):7207-11
   PubMed Web of Science ®Google Scholar
• Quinet B, Laudat A, Gurtman A, PCV-elicited antibody persistence and responses to PCV13 in children previously vaccinated with 4 doses of either PCV7 or PCV13. Poster No 200 presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 11 – 15th March 2012; Iguacu Falls, Brazil
   Google Scholar
• Ekstrom N, Simell B, Givon-Lavi N, Persistence of opsonophagocytic activity of circulating antibodies at 19 months of age after alternative PCV7 regimens in Israeli infants. Poster No 222 presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), 11 – 15th March 2012; Iguacu Falls, Brazil
   Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines 2009;8(11):1479-500
   PubMed Web of Science ®Google Scholar
• Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ 2008;86(5):373-80
   PubMed Web of Science ®Google Scholar
• Gurtman A, Tansey SP, Thompson A, Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 4 – 8 May 2010; Nice, France
   Google Scholar
• Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines 2011;10(7):951-80
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G, Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005-Apr1365(9465):1139-46
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760-8
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
   PubMed Web of Science ®Google Scholar
• Tocheva AS, Jefferies JM, Rubery H, Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011;29(26):4400-4
   PubMed Web of Science ®Google Scholar
• Elberse KE, van der Heide HG, Witteveen S, Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Rosen JB, Thomas AR, Lexau CA, CDC Emerging Infections Program Network. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis 2011;53(2):137-43
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr, Woodbury RL, Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008;197(7):1016-27
   PubMed Web of Science ®Google Scholar
• Sleeman KL, Griffiths D, Shackley F, Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006;194(5):682-8
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(49):9127-31
   PubMed Web of Science ®Google Scholar
• Safadi M. Impact of Synflorix (PHiD-CV) against pneumococcal meningitis in Brazil. 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 8 – 12th May 2012; Thessaloniki, Greece; 2012
   Google Scholar
• Swartley JS, Marfin AA, Edupuganti S, Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94(1):271-6
   PubMed Web of Science ®Google Scholar
• Malley R, Anderson PW. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci USA 2012;109(10):3623-7
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012;30(Suppl 2):B87-97
   PubMed Web of Science ®Google Scholar
• Program for Appropriate Technology in Health (PATH). Developing a thermostable polyvalent conjugate meningococcal vaccine. Available from: http://sites.path.org/vxtechnews/2011/12/thermstable-mvp/ [Accessed 20 August 2012]
   Google Scholar
• Xie O, Bolgiano B, Gao F, Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine 2012;30(40):5812-23
   PubMed Web of Science ®Google Scholar
• Joint Committee on Immunisation and Vaccination. Minute of meeting held on 13th June 2012. Available from: www.dh.gov.uk/ab/jcvi/index.htm [Accessed 19 August 2012]
   Google Scholar
• Ihssen J, Kowarik M, Dilettoso S, Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010;9:61
   PubMed Web of Science ®Google Scholar
• van Damme P, Kafeja F, Anemona A, Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011;6(9):e25398
   PubMedGoogle Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326(7385):365-6
   PubMed Web of Science ®Google Scholar
• Borgono JM, McLean AA, Vella PP, Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978;157(1):148-54
   PubMed Web of Science ®Google Scholar
• Lee GE, Lorch SA, Sheffler-Collins S, National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics 2010;126(2):204-13
   PubMed Web of Science ®Google Scholar
• Zhou F, Kyaw MH, Shefer A, Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007;161(12):1162-8
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369(9568):1179-86
   PubMed Web of Science ®Google Scholar
• Koshy E, Murray J, Bottle A, Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997 – 2008. Thorax 2010;65(9):770-4
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, de Greeff SC, Jansen AG, Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010;16(5):816-23
   PubMed Web of Science ®Google Scholar
• Durando P, Crovari P, Ansaldi F, Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria region, Italy. Vaccine 2009;27(25-26):3459-62
   PubMed Web of Science ®Google Scholar
• Stamboulidis K, Chatzaki D, Poulakou G, The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011;30(7):551-5
   PubMed Web of Science ®Google Scholar